Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Vinblastine

Generic Name: Vinblastine

Drug Type: Small Molecule

Chemical Formula: C_₄₆H_₅₈N_₄O_₉

CAS Number: 865-21-4

Unique Ingredient Identifier: 5V9KLZ54CY

Overview

Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Background

Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Indication

For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.

Associated Conditions

Advanced Soft Tissue Sarcoma
Autoimmune Hemolytic Anemia
Bladder Cancer
Hodgkin's Lymphoma
Immune Thrombocytopenia (ITP)
Kaposi's Sarcoma
Letterer-Siwe disease
Metastatic Melanoma
Non-Small Cell Lung Cancer (NSCLC)
Advanced Alibert-Bazin syndrome
Advanced Testicular cancer
Histiocytic lymphoma
Refractory Breast cancer

Clinical Trials

Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

Phase 2

Recruiting

Posted: 2025/05/22

Sponsor:

National Medical Res...

ID:NCT06984146

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Phase 3

Recruiting

Posted: 2025/05/07

Sponsor:AstraZeneca

ID:NCT06960577

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Phase 4

Recruiting

Posted: 2025/02/18

Sponsor:Takeda

ID:NCT06831370

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

Phase 2

Recruiting

Posted: 2024/12/20

Sponsor:University of Washin...

ID:NCT06745076

Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

Early Phase 1

Recruiting

Posted: 2024/04/24

Sponsor:

Daniel Morgenstern

ID:NCT06381570

FDA Approved Products

Vinblastine Sulfate

Manufacturer:Fresenius Kabi USA, LLC

Route:INTRAVENOUS

Strength:1 mg in 1 mL

Approved: 2019/12/31

NDC:63323-278

Singapore Approved Products

DBL™ VINBLASTINE INJECTION

Manufacturer:HOSPIRA AUSTRALIA PTY LTD

Form:INJECTION

Strength:1 mg/ml

Online:Yes

Approved: 1994/12/09

Approval:SIN07944P

VELBASTINE FOR INJECTION 10 mg/vial

Manufacturer:KOREA UNITED PHARMACEUTICAL INC

Form:INJECTION, POWDER, FOR SOLUTION

Strength:10 mg/vial

Online:Yes

Approved: 1999/06/24

Approval:SIN10987P

Related News

PRECISE-HL Trial Launches to Reduce Chemotherapy in Hodgkin Lymphoma Using ctDNA Testing

3 months ago

Foresight Diagnostics and University of Washington have launched the PRECISE-HL trial using ctDNA-based minimal residual disease testing to personalize treatment for advanced classical Hodgkin lymphoma patients.

Opdivo-Chemotherapy Combination Shows Promise for Elderly Hodgkin Lymphoma Patients

4 months ago

A phase 1/2 study demonstrates that Opdivo combined with AVD chemotherapy achieves 79% progression-free survival and 97% overall survival at three years in older cHL patients.

Intensity Therapeutics' Sarcoma Trial INT230-6 Authorized to Continue by DMC

5 months ago

Intensity Therapeutics' Phase 3 INVINCIBLE-3 study of INT230-6 in soft tissue sarcoma is authorized to continue without modifications after a Data Monitoring Committee review.

Nivolumab Plus AVD Emerges as New Standard for Advanced Hodgkin Lymphoma Treatment

5 months ago

Phase 3 SWOG S1826 trial demonstrates superior efficacy of nivolumab combined with AVD compared to brentuximab vedotin plus AVD in advanced-stage classic Hodgkin lymphoma.

Risk-Adapted Therapy Shows Promise in Muscle-Invasive Bladder Cancer

5 months ago

A phase II trial evaluated risk-adapted therapy after neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC).

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy